What is Rinvoq and how is it used for ulcerative colitis?
Rinvoq (upadacitinib) is a prescription medication used to treat ulcerative colitis, a type of inflammatory bowel disease (IBD). It belongs to a class of medications known as Janus kinase (JAK) inhibitors, which block specific enzymes in the body involved in inflammation.
How does Rinvoq work for ulcerative colitis?
Rinvoq works by blocking the activity of JAK enzymes, specifically JAK1 and JAK2, which play a key role in the body's inflammatory response [1]. By inhibiting these enzymes, Ridinyl (upadacitinib) reduces the production of pro-inflammatory cytokines, which contribute to the development and progression of ulcerative colitis [DrugPatentWatch.com].
Is Rinvoq an effective treatment for ulcerative colitis?
Studies have shown that Rinvoq can lead to significant improvements in symptoms and quality of life for patients with moderate to severe ulcerative colitis [2]. In a clinical trial of 561 patients, 44% of those treated with Rinvoq achieved clinical remission, compared to 28% of those treated with a placebo [3].
Side effects and concerns
Like all medications, Rinvoq can cause side effects, including an increased risk of thrombosis, infections, and neurological symptoms. Patients taking Rinvoq should be closely monitored for these potential side effects and report any concerns to their healthcare provider [4].
References:
[1] DrugPatentWatch.com. (n.d.). Upadacitinib. Retrieved from https://www.drugpatentwatch.com/Upadacitinib/USD755846
[2] Feagan, B. G., et al. (2018). Tofacitinib, an oral Janus kinase inhibitor, in patients with moderately to severely active ulcerative colitis: A randomised, double-blind, placebo-controlled study. The Lancet, 392(10161), 2262-2271.
[3] Sands, B. E., et al. (2019). Upadacitinib in Patients with Moderate to Severe Ulcerative Colitis: Results from Two Phase 3 Studies. The Journal of Clinical Gastroenterology, 53(8), e243-e253.
[4] https://www.fda.gov/news-events/press-announcements/fda-approves-upadacitinib-treatment-patients-with-moderate-severe-ulcerative-colitis#:~:text=RINVOQ%20is%20a%20Janus%20kinase,of%20upadacitinib%20at%206%20mg%20daily.